Publication | Closed Access

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Open-label Phase 3MedicinePathologyLiver MetastasesCancer TreatmentCancer GeneticsOncologyRadiation OncologyKey Subgroup AnalysesLung CancerMolecular Oncology